Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.51 |
| ▸ | ITK | Q08881 | 7/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 2/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24969099 | 0.94 | EGFR (0.52) | EGFRITKEPHX2TGM2BRAF | |
| SCHEMBL28456327 | 0.82 | EGFR (0.69) | EGFRITKTGM2KDR | |
| SCHEMBL24969095 | 0.78 | EGFR (0.50) | EGFRITKTGM2 | |
| SCHEMBL24968812 | 0.77 | EGFR (0.54) | EGFRITKTGM2S1PR5 | |
| SCHEMBL24969097 | 0.76 | EGFR (0.49) | EGFRITKTGM2BRAFKDR | |
| SCHEMBL24969100 | 0.76 | EGFR (0.47) | EGFRITKTGM2 | |
| SCHEMBL24969151 | 0.75 | S1PR1 (0.52) | EGFRITKTGM2BRAFKDR | |
| SCHEMBL24968859 | 0.75 | EGFR (0.51) | EGFRITKTGM2KDR | |
| SCHEMBL24969098 | 0.74 | TGM2 (0.51) | EGFRITKTGM2 | |
| SCHEMBL24968513 | 0.74 | DHODH (0.50) | EGFRITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023009785-A1 | TEAD INHIBITORS AND USES THEREOF | CEDILLA THERAPEUTICS, INC. (US) | 2023-02-02 | — | — | WO | disclosed |